Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer
Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential.
Nuvalent Inc. (NUVL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deerfield Management James E. Flynn | 17,991,024 | $1,275,923,422 | 25.19% | |
| 2. | Commodore Capital Egen Atkinson And Michael Kramarz | 1,855,000 | $131,556,600 | +15% | 9.69% |
| 3. | Perceptive Advisors Joseph Edelman | 1,633,968 | $115,881,011 | -38% | 4.08% |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 1,205,531 | $85,496,259 | +1% | 0.56% |
| 5. | Vestal Point Capital Ryan Wilder | 1,075,000 | $76,239,000 | +80% | 5.44% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $33.50 | 650,000 | $21,775,000.00 | 650,000 | 2022-11-03 | Filing | |
| $33.50 | 149,253 | $4,999,975.50 | 3,577,267 | 2022-11-03 | Filing | |
| $17.00 | 735,000 | $12,495,000.00 | 3,428,014 | 2021-08-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $85.10 | 14,700 | $1,250,970.00 | 61,734 | 2025-07-16 | Filing | |
| $85.48 | 54 | $4,615.92 | 61,734 | 2025-07-15 | Filing | |
| $84.91 | 874 | $74,211.34 | 61,788 | 2025-07-15 | Filing | |
| $83.87 | 1,888 | $158,346.56 | 62,662 | 2025-07-15 | Filing | |
| $82.67 | 2,484 | $205,352.28 | 64,550 | 2025-07-15 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,000 | $228,900 | 0.06% | |
| 2. | 1,213 | $92,552 | 0% | |
| 3. | 350 | $26,705 | 0.02% | |
| 4. | 194 | $14,802 | 0% | |
| 5. | 124 | $9,461 | 0% |
News See All
10 Best High Short Interest Stocks With Huge Upside Potential
Abby Yoder, JPMorgan Private Bank's chief equity strategist, joined CNBC's 'Closing Bell' on July 2 to discuss the market's momentum as stocks began the second half of the year. Yoder confirmed her continued...
20 Takeover Rumors Hedge Funds Are Buying
Hedge funds tend to pile up on a stock that gains or is expected to gain positive attention in a market.
11 Best Guru Stocks to Buy According to Wall Street Analysts
Wall Street seems to be breathing a little easier after the initial panic over President Trump’s tariffs earlier this month, but the rollercoaster is not over just yet.
10 Best Debt Free Mid Cap Stocks to Buy Now
Debt-free mid-cap stocks currently offer compelling investment opportunities, especially in today's high-interest-rate environment.
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
10 Mid-Cap Stocks Insiders Are Selling Recently
Why should investors analyze insider trading activity? Insiders, or people in high positions within a company—such as executives and directors—can have crucial insights into the company’s strategic...
Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks
Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology and healthcare investing.
10 Largest Biotech Hedge Funds and Their Top Stock Picks
The ability to successfully make money through investment requires deep thinking and analysis.
10 Worst Cancer Stocks To Buy Now According to Short Sellers
Cancer is the second leading cause of death globally, just behind cardiovascular disease, making oncology one of the largest sectors in the life sciences.
Billionaire Hedge Funds
